Sangamo Therapeutics Inc (NASDAQ:SGMO) CFO Kathy Yi Sells 5,000 Shares

Sangamo Therapeutics Inc (NASDAQ:SGMO) CFO Kathy Yi sold 5,000 shares of the stock in a transaction on Monday, October 15th. The stock was sold at an average price of $13.97, for a total value of $69,850.00. Following the completion of the transaction, the chief financial officer now owns 12,250 shares in the company, valued at $171,132.50. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Kathy Yi also recently made the following trade(s):

  • On Monday, September 17th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The stock was sold at an average price of $14.66, for a total value of $73,300.00.
  • On Thursday, August 16th, Kathy Yi sold 5,000 shares of Sangamo Therapeutics stock. The shares were sold at an average price of $15.39, for a total value of $76,950.00.

Shares of Sangamo Therapeutics stock traded down $2.46 during trading hours on Friday, hitting $11.16. 5,698,240 shares of the company’s stock traded hands, compared to its average volume of 1,634,710. Sangamo Therapeutics Inc has a 12-month low of $11.02 and a 12-month high of $27.50. The firm has a market cap of $1.45 billion, a PE ratio of -15.94 and a beta of 3.21. The company has a debt-to-equity ratio of 0.07, a current ratio of 7.24 and a quick ratio of 7.24.

Sangamo Therapeutics (NASDAQ:SGMO) last announced its quarterly earnings data on Thursday, November 8th. The biopharmaceutical company reported ($0.13) earnings per share for the quarter, topping the consensus estimate of ($0.15) by $0.02. Sangamo Therapeutics had a negative return on equity of 26.36% and a negative net margin of 105.65%. The company had revenue of $23.56 million during the quarter, compared to analyst estimates of $26.96 million. During the same quarter last year, the firm posted ($0.15) EPS. The firm’s revenue for the quarter was up 99.5% on a year-over-year basis. As a group, equities analysts anticipate that Sangamo Therapeutics Inc will post -0.69 EPS for the current fiscal year.

Institutional investors and hedge funds have recently made changes to their positions in the stock. United Services Automobile Association increased its holdings in Sangamo Therapeutics by 9.2% in the 2nd quarter. United Services Automobile Association now owns 57,633 shares of the biopharmaceutical company’s stock worth $818,000 after acquiring an additional 4,860 shares during the last quarter. Wells Fargo & Company MN increased its holdings in Sangamo Therapeutics by 42.2% in the 2nd quarter. Wells Fargo & Company MN now owns 789,981 shares of the biopharmaceutical company’s stock worth $11,218,000 after acquiring an additional 234,346 shares during the last quarter. Schwab Charles Investment Management Inc. boosted its stake in Sangamo Therapeutics by 14.4% in the 2nd quarter. Schwab Charles Investment Management Inc. now owns 565,601 shares of the biopharmaceutical company’s stock worth $8,032,000 after purchasing an additional 71,134 shares during the period. Platinum Investment Management Ltd. bought a new position in Sangamo Therapeutics in the 2nd quarter worth about $751,000. Finally, Bain Capital Public Equity Management LLC bought a new position in Sangamo Therapeutics in the 2nd quarter worth about $2,002,000. 64.01% of the stock is owned by institutional investors.

Several equities analysts have weighed in on the company. BidaskClub upgraded Sangamo Therapeutics from a “hold” rating to a “buy” rating in a research note on Wednesday, September 5th. Zacks Investment Research upgraded Sangamo Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, August 14th. Wedbush restated a “hold” rating and set a $10.00 price objective on shares of Sangamo Therapeutics in a research note on Thursday, August 9th. ValuEngine cut Sangamo Therapeutics from a “strong-buy” rating to a “buy” rating in a research note on Thursday, September 6th. Finally, Cowen reaffirmed a “buy” rating on shares of Sangamo Therapeutics in a research report on Monday, July 23rd. One equities research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus target price of $21.00.

WARNING: This report was published by Baseball Daily News and is owned by of Baseball Daily News. If you are reading this report on another domain, it was illegally copied and reposted in violation of U.S. and international copyright and trademark law. The legal version of this report can be read at https://www.baseballdailydigest.com/2018/11/10/sangamo-therapeutics-inc-sgmo-cfo-sells-69850-00-in-stock.html.

About Sangamo Therapeutics

Sangamo Therapeutics, Inc focuses on translating science into genomic therapies that transform patients' lives using platform technologies in genome editing, gene therapy, gene regulation, and cell therapy. The company's zinc finger DNA-binding protein (ZFP) technology enables specific genome editing and gene regulation.

See Also: What is the Rule of 72?

Insider Buying and Selling by Quarter for Sangamo Therapeutics (NASDAQ:SGMO)

Receive News & Ratings for Sangamo Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sangamo Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply